Related Experiment Video

Updated: May 27, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Genomics and cancer drug resistance

Antonio S Rodrigues1, Joana Dinis, Marta Gromicho

  • 1CIGMH - Department of Genetics, Universidade Nova de Lisboa, Lisboa, Portugal. seba.gene@fcm.unl.pt

Current Pharmaceutical Biotechnology
|November 30, 2011
PubMed

Insights

Genomic studies reveal key pathways in cancer drug resistance, highlighting microRNAs and tyrosine kinase inhibitors. This research aims to improve cancer drug development and patient outcomes by identifying novel molecular targets.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Cellular drug resistance is a significant challenge in cancer therapy, leading to poor patient prognosis.
  • Mechanisms include altered transporter expression (e.g., ABC transporters causing multi-drug resistance), DNA repair pathway changes, apoptosis resistance, and target modifications.
  • Current anti-cancer treatments (chemotherapy, hormonal, targeted drugs, antibodies) face resistance, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the impact of genomics on understanding cancer drug resistance pathways.
  • To explore the role of microRNAs in regulating gene expression and contributing to drug resistance.
  • To examine specific resistance mechanisms against tyrosine kinase inhibitors in chronic myeloid leukemia.

Main Methods:

  • Review of existing literature on cancer drug resistance mechanisms.
  • Analysis of genomic data and its application in identifying drug resistance pathways.
  • Focus on microRNA functions and their involvement in acquired resistance.
  • Detailed examination of resistance to tyrosine kinase inhibitors in CML.

Main Results:

  • Genomics provides critical insights into complex cancer drug resistance mechanisms.
  • MicroRNAs emerge as key regulators influencing cellular responses to anti-cancer drugs.
  • Specific molecular targets and pathways involved in resistance to tyrosine kinase inhibitors have been identified.

Conclusions:

  • Understanding the genomic underpinnings of drug resistance is vital for developing more effective cancer therapies.
  • Targeting microRNAs and specific resistance pathways offers potential for overcoming treatment failures.
  • Continued research into novel molecular targets is essential for improving cancer drug development and patient survival.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...